18 results about "Cellular Autophagy" patented technology

This invention provides a highly water-soluble composition for promoting autophagy and its application. The composition comprises 5-hydroxyflavone, acetylhydroxyproline, and a suitable solvent. This composition is a unique vesicular composition that enables efficient delivery and synergistic effects of the two active ingredients. It promotes autophagy, has improved solubility, stability, and antioxidant properties, and can prevent and repair skin photodamage at its source. This invention also discloses a method for preparing this composition and its applications.

The invention belongs to the technical field of biology, discloses a composition for promoting cell autophagy and application, particularly relates to application of a composition comprising ergothioneine and an M6P composite solution to preparation of a cell autophagy composition, and provides a composition capable of synergistically promoting cell autophagy. According to the composition, cell autophagy is synergistically promoted by inhibiting expression of p62 protein and promoting expression of LC3II protein in a specific proportion, so that cells are accelerated to remove metabolic disorder substances and deposited pigments in a manner of forming autophagosomes.

This application relates to the technical field of biological products, and provides an application, extraction method and composition of TGL-ELNs in the treatment of glioma. The TGL-ELNs are applied in any one or more of the following aspects: a) Preparation of products for promoting apoptosis of glioma cells; b) Preparation of products for inhibiting proliferation of glioma cells; c) Preparation of products for inhibiting autophagy of glioma cells; d) Preparation of products for treating glioma. Verified through cell and animal experiments, the TGL-ELNs in this application can effectively induce apoptosis of glioma cells and inhibit autophagy of glioma cells to induce glioma cell death, and act on glioma cells through the AKT / mTOR signaling pathway and by inhibiting the production of autophagosomes in glioma cells.

The invention discloses application of MYSM1 regulation and control of ITPR1 mediated cell autophagy in inhibition of cervical cancer, and belongs to the technical field of biomedicine.The MYSM1 gene and / or expression or activity of encoded protein of the MYSM1 gene are / is up-regulated, and an MYSM1-ITPR1-autophagy signal channel is activated, so that proliferation, migration, invasion or epithelial-mesenchymal transition of cervical cancer cells is inhibited, and cervical cancer is inhibited. And / or promoting apoptosis of cervical cancer cells; wherein the MYSM1 activates the expression of ITPR1 through the activity of a deubiquitination enzyme which is subjected to single ubiquitination modification on the 119th lysine of histone H2A of the MYSM1, and the ITPR1 serves as an endoplasmic reticulum calcium ion channel to mediate calcium ion release so as to trigger cell autophagy. Based on the mechanism, the invention provides a new application of MYSM1 / ITPR1 in preparation of anti-cervical cancer drugs, a drug composition targeting the pathway, a candidate drug screening method and a kit for diagnosis and prognosis. The invention aims to solve the problem that a technical scheme for effectively inhibiting the malignant progression of cervical cancer by targeting an MYSM1-ITPR1 pathway is lacked in the prior art.

The invention relates to application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine. Rat and SH-SY5Y cell experiments are carried out, and the rat experiments prove that after intervention of different doses of GSPE, the SOD activity and the GSH content are improved, the MDA level is reduced, the antioxidant capacity of rats is recovered, autophagy is promoted, the filial generation learning and memory retention capacity is remarkably recovered, the autonomous activity capacity is recovered, anxiety behaviors are reduced, the occurrence and development processes of dental fluorosis are slowed down, and the occurrence and development of dental fluorosis are promoted. The change trends of different doses of GSPE present dose dependence, and the protection effect of a high-dose combined intervention group is most significant; in an SH-SY5Y cell experiment, the activity of the cells is improved through GSPE pretreatment, the expression quantity of cleave-caspase3 and cleaved-PARP is remarkably reduced, the autophagy process of the SH-SY5Y cells is promoted, and then the neurotoxicity caused by NaF is relieved. NaF is used as a representative, the prevention and treatment effects of GSPE on the fluorine-induced neurotoxicity are researched, and it is proved that GSPE can inhibit the NaF-induced neurotoxicity, so that the application of autophagy in preparation of drugs or health food for improving the fluorine-induced neurotoxicity from grape seed procyanidine is provided.

The invention discloses a zebrafish cell autophagy rapid detection kit. The kit comprises a rapid RNA extraction column, and a matched lysis solution, a washing solution, an eluent, DNase I, a reverse transcription premix solution, a qPCR premix solution, and a dry powder or premix solution of a specific primer. The invention also discloses an application of the kit. The invention also discloses a method for screening compounds or substances for regulating and controlling zebrafish cell autophagy by using the kit. According to the invention, brand new high-specificity and high-efficiency primers are adopted, so that false positive and background noise are remarkably reduced, and detection data of expression quantities of LC3B and p62 genes are more real and reliable; the optimized integration process greatly shortens the detection time; the premixed reagents and the standardized operation process ensure good reproducibility of experimental results of different batches and different operators.

The invention relates to the field of biosensing, in particular to a genetic coding fluorescent probe for detecting lactic acid change in autophagosome and application of the genetic coding fluorescent probe. The invention discloses a genetic coding fluorescent probe for detecting lactic acid change in an autophagy body, which comprises an FRET pair, a lactic acid sensing structural domain and an autophagy body targeting structural domain and is used for specifically detecting the lactic acid concentration change in the autophagy body in real time, when the lactic acid concentration in the autophagy body changes, the conformation of the probe changes, and the change of the lactic acid concentration in the autophagy body changes. As a result, the fluorescence resonance energy transfer efficiency changes, and dynamic, non-invasive and high-temporal-spatial-resolution detection of the concentration of the lactic acid in the autophagy body can be realized by monitoring the change of the FRET ratio.

The invention discloses an application of benzothiazide in preparation of a medicine for preventing or treating Alzheimer's disease. Specifically, the benzene thiazide can reduce the paralysis rate of an Alzheimer's disease caenorhabditis elegans model, reduce beta amyloid protein aggregation, improve immune response and promote cell autophagy. The invention provides a new treatment scheme for treating the Alzheimer's disease.

The application discloses an immune cell autophagy marker detection kit and belongs to the technical field of biomedical detection, comprising two kinds of fluorescent coding microsphere mixtures coupled with anti-LC3B-II and p62 / SQSTM1 capture antibodies respectively, a biotinylated detection antibody mixture, a streptavidin-phycoerythrin conjugate, six-point calibrators (S0-S5), a quality control product, a cell lysis buffer containing non-ionic and zwitterionic surfactants and 4 mol / L urea, and data analysis software based on LC3B-II / p62 natural logarithm ratio output autophagy activity comprehensive score.

The application belongs to the technical field of natural medicine, and particularly relates to application of spermidine alkaloids in preparation of anti-tumor drugs and / or reversal of drug resistance. The application provides application of macrocyclic spermidine alkaloids in preparation of anti-tumor drugs and / or reversal of drug resistance, wherein the macrocyclic spermidine alkaloids include one or more than two of 13-oxo-furanic Rauwolfia serpentina, furanic Rauwolfia serpentina, benzyl Rauwolfia serpentina and Rauwolfia serpentina cinnamylamide base. The macrocyclic spermidine alkaloids have the characteristics of wide spectrum of anti-tumor effect, good anti-tumor effect, low toxic and side effect, reversal of 5-fluorouracil drug resistance, high water solubility, easy source, simple structure, only one chiral carbon in the structure, easy artificial synthesis, intervention of cell autophagy mechanism and the like, so that the overall treatment cost is low, and the macrocyclic spermidine alkaloids have potential important clinical application prospect.

This invention belongs to the field of zoonotic disease prevention and control and molecular immunology technology, specifically relating to the application of a biological product that silences or knocks out the ID2 gene in regulating host resistance to Brucella infection. This invention constructs an ID2 gene knockout macrophage model using CRISPR / Cas9 gene editing technology and establishes a Brucella infection system. Experiments show that ID2 gene knockout significantly enhances the host's ability to clear Brucella. RNA-seq analysis shows that ID2 participates in regulating the host's transcriptional response network to Brucella, with its differentially expressed genes significantly enriched in lipid metabolism and autophagy. Mechanistic results indicate that the ID2 gene participates in the regulation of Brucella-mediated lipophage. It can be seen that the ID2 gene affects the intracellular replication level and lipophage process of Brucella. This invention provides new targets and theoretical basis for drug development against Brucella infection, immune regulation, and disease-resistant breeding.

This application discloses the use of tetrandrine in the preparation of products for treating autophagy-related diseases. Through research, this application found that tetrandrine can significantly induce autophagy and promote TFEB nuclear translocation, making it suitable as an autophagy inducer and TFEB activator. Furthermore, it is naturally derived, has low toxicity, and high activity, providing a safe and effective new strategy for treating autophagy-related diseases, especially Gaucher disease, a lysosomal storage disorder.

The invention relates to means and methods for the treatment of diseases involving autophagy by cells, which process according to the invention is involved in mechanisms of tissue repair, vascular permeability and immune responses. The invention provides methods and means to target the elastin receptor complex specifically and to provide molecules and compositions comprising a specific targeting agent as well as amino acid compositions that are involved in the pathway of autophagy and the diseases related thereto. The disclosure also relates to peptide-drug development, in particular to (the improvement of) autophagy inhibiting amino acid containing peptides, more in particular glutamine-containing peptides and / or glutamine and other autophagy modulating amino acid containing compositions useful in the treatment of vascular and inflammatory conditions. The invention further relates to the improvement of glutamine peptides useful in the treatment of diabetic, vascular and / or inflammatory conditions. The invention provides a Q- ER peptide, comprising a synthetic peptide or functional analogue thereof provided with at least one PG-domain amino acid motif xGxxPG or functional equivalent thereof, said PG- domain motif allowing targeting of said peptide to the elastin receptor complex (ER), wherein at least one amino acid at position x is selected from the group of amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine, said peptide provided with at least one glutamine (Q).

The invention relates to a herba epimedii extract for activating cell autophagy and a preparation method and application thereof.The herba epimedii extract is prepared from specific zymophyte and compound enzyme, the content of icariside I in the herba epimedii extract is increased, and the herba epimedii extract can activate cell autophagy by up-regulating expression of lysosome mannosidase (LManV). The composition has the advantages that the autophagy flow of cells is obviously enhanced, the fusion of autophagosome and lysosome is promoted, the p62 / Ref( 2) P accumulation caused by the decline of the autophagy function is efficiently reversed, the steady state of the environment in the cells is maintained, the aging speed of the cells is delayed, the support is provided for the aging resistance of the organism from the cellular level, the improvement of the aging-related physical state and the maintenance of the vitality of the organism are helped, and the composition is safe and non-toxic to the human body.

The present application relates to a kind of activation of cell autophagy Epimedium extract and its preparation method and application, the present application is prepared using specific fermentation bacteria and composite enzyme Epimedium extract, improve the content of Epimedium in Epimedium extract Epimedium secondary glycoside I, the Epimedium extract can be up-regulated lysosome mannose glycosidase (LManV) expression, significantly enhance cell autophagy flow, promote autophagosome and lysosome fusion, efficiently reverse the p62 / Ref (2) P accumulation caused by autophagy function decline, maintain intracellular environment steady, delay cell aging speed, provide support for organism anti-aging from cell level, help to improve the physical condition related to aging, maintain organism activity, and safe and nontoxic to human body.

The invention discloses an application of stenotrophomonas maltophilia in preparation of a medicine for preventing or treating Alzheimer's disease. Specifically, the stenotrophomonas maltophilia has the purposes of reducing beta amyloid protein aggregation, relieving learning and memory impairment, promoting autophagy and the like, and an effective scheme is provided for preventing and treating the Alzheimer's disease.

The present disclosure addresses the problem of providing a novel autophagy inducer.　The present disclosure pertains to an autophagy inducer containing a triterpene compound, and the like. In particular, the autophagy-inducing action of cells is effectively promoted by containing an oleanane-type triterpene having a five-ring structure, oleanolic acid, an olive leaf extract, a Ligustrum lucidum extract, and the like. Said autophagy inducer can be formulated as a solid composition, a food and drink composition, a cosmetic, or a medicine, and an excipient can also be used in combination.